AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38590997 — intervention group
Group type: COMPARATOR
Intervention: Endocardial catheter ablation (CA)
Number of subjects: 153
Study 38591096 — intervention group
Group type: EXPERIMENTAL
Intervention: DaVinci RARP (DV-RARP)
Number of subjects: 100
Study 38591096 — intervention group
Group type: COMPARATOR
Intervention: Hugo RAS (H-RARP)
Number of subjects: 100
Study 38591260 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten, 5 mg once daily with individualized dose titration at week 6
Number of subjects: 13
Study 38591535 — intervention group
Group type: EXPERIMENTAL
Intervention: Vienna transcatheter aortic valve system
Number of subjects: 10
Study 38591600 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrestricted diet
Number of subjects: 102
Study 38591600 — intervention group
Group type: COMPARATOR
Intervention: 3-day low-residue diet
Number of subjects: 102
Study 38591748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase within 4.5 hours of symptom onset
Number of subjects: 422
Study 38591748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study 38591748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 422
Study 38591808 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth extraction (TE)
Number of subjects: 156
Study 38591808 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for osteotomy
Number of subjects: 156
Study 38591808 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose at the extraction site
Number of subjects: 156
Study 38591811 — intervention group
Group type: COMPARATOR
Intervention: Mibavademab (0.3, 1.0, 3.0, 10, and 30 mg/kg i.v. or 300 and 600 mg subcutaneous)
Number of subjects: 111
Study 38591811 — intervention group
Group type: COMPARATOR
Intervention: Mibavademab (15 mg/kg i.v. loading dose and 10 mg/kg i.v. at weeks 3, 6, and 9)
Number of subjects: 111
Study 38591811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 38591829 — intervention group
Group type: EXPERIMENTAL
Intervention: iFightDepression-SURVIVE (iFD-S) with treatment as usual (TAU)
Number of subjects: 60
Study 38591829 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 60
Study 38591949 — intervention group
Group type: EXPERIMENTAL
Intervention: PARDSEVERE risk model for mortality on day 0
Number of subjects: 279
Study 38591949 — intervention group
Group type: EXPERIMENTAL
Intervention: PARDSEVERE risk model for mortality on day 3
Number of subjects: 279
Study 38591949 — intervention group
Group type: EXPERIMENTAL
Intervention: PARDSEVERE risk model for mortality on day 7
Number of subjects: 279
Study 38591949 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative predictive value (NPV) for all three time points
Number of subjects: 279
Study 38591997 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of coronary artery calcium score (Ca-score) and high-sensitivity cardiac troponin T (hs-cTnT)
Number of subjects: 1715
Study 38591997 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI)
Number of subjects: 1715
Study 38591997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca-score and hs-cTnT
Number of subjects: 1715
Study 38591997 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite of cardiovascular death and non-fatal acute myocardial infarction (AMI)
Number of subjects: 1715
Study 38592002 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 1350
Study 38592002 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 1350
Study 38592485 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated oxygen control (AOC)
Number of subjects: 0
Study 38592485 — intervention group
Group type: COMPARATOR
Intervention: Manual oxygen control
Number of subjects: 0
Study 38592605 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid cycling bipolar disorder (RCBD)
Number of subjects: 520
Study 38592721 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-EGFR rechallenge therapy (including cetuximab plus avelumab, trifluridine-tipiracil plus panitumumab, irinotecan plus cetuximab, or panitumumab monotherapy)
Number of subjects: 114
Study 38592721 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-EGFR rechallenge therapy (in patients without liver metastasis)
Number of subjects: 114
Study 38592721 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-EGFR rechallenge therapy (in patients with liver metastasis)
Number of subjects: 114
Study 38592753 — intervention group
Group type: EXPERIMENTAL
Intervention: NUTRES mHealth intervention (SMS text messages)
Number of subjects: 494
Study 38592753 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 494
Study 38592771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindset for Depression app with 8 brief video conferencing visits with a licensed CBT therapist
Number of subjects: 28
Study 38592771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindset for Depression app
Number of subjects: 28
Study 38593212 — intervention group
Group type: EXPERIMENTAL
Intervention: 225Ac-macropa-pelgifatamab (225Ac-pelgi)
Number of subjects: 0
Study 38593212 — intervention group
Group type: COMPARATOR
Intervention: 225Ac-DOTA-pelgi
Number of subjects: 0
Study 38593212 — intervention group
Group type: COMPARATOR
Intervention: 225Ac-DOTA-J591
Number of subjects: 0
Study 38593212 — intervention group
Group type: COMPARATOR
Intervention: 227Th-HOPO-pelgifatamab (227Th-pelgi)
Number of subjects: 0
Study 38593212 — intervention group
Group type: EXPERIMENTAL
Intervention: 225Ac-pelgi
Number of subjects: 0
Study 38593212 — intervention group
Group type: EXPERIMENTAL
Intervention: 225Ac-pelgi with darolutamide
Number of subjects: 0
Study 38593221 — intervention group
Group type: COMPARATOR
Intervention: Leniolisib
Number of subjects: 6
Study 38593233 — intervention group
Group type: EXPERIMENTAL
Intervention: Posoleucel infusion initiated within 15 to 49 days of allo-HCT, subsequently every 14 days for up to 7 doses.
Number of subjects: 26
Study 38593233 — intervention group
Group type: EXPERIMENTAL
Intervention: Posoleucel infusion
Number of subjects: 26
Study 38593241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan therapy
Number of subjects: 80
Study 38593249 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (1 g/day)
Number of subjects: 110
Study 38593249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 38593348 — intervention group
Group type: EXPERIMENTAL
Intervention: RMC-6236 at 300 mg daily
Number of subjects: 2
Study 38593348 — intervention group
Group type: EXPERIMENTAL
Intervention: RMC-6236 at 100 mg and 300 mg daily
Number of subjects: 2
Study 38593428 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth parenting intervention delivered to caregivers
Number of subjects: 149
Study 38593428 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 149
Study 38593512 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib 250 mg once daily for 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle
Number of subjects: 9
Study 38593512 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib 200 mg once daily for 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle
Number of subjects: 9
Study 38593943 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD education and screening (blood pressure, electrocardiogram, transthoracic echocardiogram [TTE])
Number of subjects: 498
Study 38593947 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran (284 mg at days 0, 90, and 270) plus usual care
Number of subjects: 450
Study 38593947 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 450
Study 38594150 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD)
Number of subjects: 772
Study 38594150 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal Replacement Therapy (RRT)
Number of subjects: 772
Study 38594150 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine/Epinephrine treatment
Number of subjects: 772
Study 38594150 — intervention group
Group type: COMPARATOR
Intervention: Invasive ventilation
Number of subjects: 772
Study 38594150 — intervention group
Group type: COMPARATOR
Intervention: Mechanical circulatory support
Number of subjects: 772
Study 38594181 — intervention group
Group type: EXPERIMENTAL
Intervention: Any antenatal care (ANC)
Number of subjects: 8575
Study 38594181 — intervention group
Group type: EXPERIMENTAL
Intervention: Four or more ANC visits
Number of subjects: 8575
Study 38594181 — intervention group
Group type: EXPERIMENTAL
Intervention: First ANC visit in the first trimester
Number of subjects: 8575
Study 38594181 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance to nearest facility
Number of subjects: 8575
Study 38594181 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional ANC visit
Number of subjects: 8575
Study 38594181 — intervention group
Group type: EXPERIMENTAL
Intervention: First ANC in the first trimester
Number of subjects: 8575
Study 38594181 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutional delivery
Number of subjects: 8575
Study 38594245 — intervention group
Group type: EXPERIMENTAL
Intervention: WU-04 (non-covalent inhibitor)
Number of subjects: 0
Study 38594245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensitrelvir and nirmatrelvir (clinically used inhibitors)
Number of subjects: 0
Study 38594322 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke-induced immunosuppression (SII)
Number of subjects: 0
Study 38594435 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing adalimumab (ADA) dose intervals to 3 and then to 4 weeks.
Number of subjects: 109
Study 38594435 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing adalimumab (ADA) dose intervals.
Number of subjects: 109
Study 38594435 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model based on logistic regression with relaxed LASSO.
Number of subjects: 109
Study 38594558 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperpolarized [1-
Number of subjects: 6
Study 38594603 — intervention group
Group type: EXPERIMENTAL
Intervention: GARD-optimized doses with simultaneous integrated boost (SIB) doses of 70 and 60 Gy in 25 fractions to the highest and intermediate radioresistant habitats, while the remaining volume receives standard 50 Gy
Number of subjects: 0
Study 38594603 — intervention group
Group type: EXPERIMENTAL
Intervention: mpMRI taken between weeks two and three of treatment
Number of subjects: 0
Study 38594603 — intervention group
Group type: EXPERIMENTAL
Intervention: mpMRI after completion of radiotherapy
Number of subjects: 0
Study 38594603 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid biopsy with mpMRI
Number of subjects: 0
Study 38594621 — intervention group
Group type: EXPERIMENTAL
Intervention: BCHE-K carriers (n=11)
Number of subjects: 45
Study 38594621 — intervention group
Group type: COMPARATOR
Intervention: BCHE-K noncarriers (n=22)
Number of subjects: 45
Study 38594621 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE4 carriers (N=33)
Number of subjects: 45
Study 38594621 — intervention group
Group type: COMPARATOR
Intervention: APOE4 noncarriers (N=12)
Number of subjects: 45
Study 38594621 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 45
Study 38594680 — intervention group
Group type: EXPERIMENTAL
Intervention: GGOC-AD mobile app intervention module for 14 days
Number of subjects: 55
Study 38594680 — intervention group
Group type: COMPARATOR
Intervention: GGN-AD non-active module (control)
Number of subjects: 55
Study 38594685 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated health system-mediated strategy
Number of subjects: 220
Study 38594685 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonprofit foundation-mediated strategy with contact from a foundation-employed care navigator
Number of subjects: 220
Study 38594685 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 220
Study 38594710 — intervention group
Group type: EXPERIMENTAL
Intervention: Austrian OA Cuisine combined with GLA:D® programme
Number of subjects: 60
Study 38594710 — intervention group
Group type: COMPARATOR
Intervention: General information about a healthy lifestyle
Number of subjects: 60
Study 38594727 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised robot-assisted therapy
Number of subjects: 13
Study 38594725 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I with bright light therapy
Number of subjects: 150
Study 38594725 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-I with placebo light
Number of subjects: 150
Study 38594725 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 150
Study 38594733 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Integrated Care (FICare)
Number of subjects: 0
Study 38594733 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 38594737 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional-Cognitive and Sensory Treatment (F-CaST)
Number of subjects: 48
Study 38594737 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 48
Study 38594740 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 84
Study 38594740 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person communication, multidisciplinary review, and medical record documentation
Number of subjects: 84
Study 38594740 — intervention group
Group type: EXPERIMENTAL
Intervention: COM-B domains (Opportunity-Social, Motivation-Reflective)
Number of subjects: 84
Study 38594756 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-protein, high-fiber (LFHP) diet
Number of subjects: 93
Study 38594756 — intervention group
Group type: COMPARATOR
Intervention: High in mono-unsaturated fatty acids (HMUFA) diet
Number of subjects: 93
Study 38594905 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus chemotherapy (Sin+Chemo)
Number of subjects: 0
Study 38594905 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Chemo)
Number of subjects: 0
Study 38595129 — intervention group
Group type: EXPERIMENTAL
Intervention: YYS 360
Number of subjects: 1022
Study 38595129 — intervention group
Group type: EXPERIMENTAL
Intervention: YYS 540
Number of subjects: 1022
Study 38595129 — intervention group
Group type: EXPERIMENTAL
Intervention: YYS 720
Number of subjects: 1022
Study 38595232 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-derived cell-free DNA (dd-cfDNA) testing
Number of subjects: 424
Study 38595232 — intervention group
Group type: COMPARATOR
Intervention: Serum creatinine levels
Number of subjects: 424
Study 38595232 — intervention group
Group type: COMPARATOR
Intervention: Increased dd-cfDNA results (≥1%)
Number of subjects: 424
Study 38595294 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention plus weight-bearing walking training
Number of subjects: 0
Study 38595294 — intervention group
Group type: COMPARATOR
Intervention: Weight-bearing walking training alone
Number of subjects: 0
Study 38595692 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 233
Study 38595771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentored community gardening intervention
Number of subjects: 0
Study 38596254 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal metronidazole for 5 days before hysterectomy
Number of subjects: 133
Study 38596254 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 133
Study 38596329 — intervention group
Group type: EXPERIMENTAL
Intervention: ESPRIMO intervention
Number of subjects: 53
Study 38596515 — intervention group
Group type: EXPERIMENTAL
Intervention: SinergiAPS intervention (patient-centered audit and feedback) with two audits (baseline and intermediate at 12 months) and educational resources.
Number of subjects: 118
Study 38596515 — intervention group
Group type: EXPERIMENTAL
Intervention: SinergiAPS intervention (patient-centered audit and feedback).
Number of subjects: 118
Study 38596515 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 118
Study 38596789 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnout syndrome measured using the Maslach Burnout Inventory
Number of subjects: 104
Study 38596789 — intervention group
Group type: COMPARATOR
Intervention: Comparison with previous survey results from 2018
Number of subjects: 104
Study 38596929 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld device
Number of subjects: 110
Study 38596929 — intervention group
Group type: COMPARATOR
Intervention: Cart-based model
Number of subjects: 110
Study 38597172 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ticagrelor (60 mg twice a day)
Number of subjects: 39
Study 38597172 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (75 mg once a day)
Number of subjects: 39
Study 38597214 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose group (LDG) receiving 8 mg cyproheptadine and 5 mg prazosin ER daily
Number of subjects: 154
Study 38597214 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group (HDG) receiving 12 mg cyproheptadine and 10 mg prazosin ER daily
Number of subjects: 154
Study 38597214 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PG) receiving placebo of cyproheptadine and prazosin ER
Number of subjects: 154
Study 38597249 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-based attendance strategy (daily rapid antigen testing and staying at work if the test is negative)
Number of subjects: 16014
Study 38597249 — intervention group
Group type: COMPARATOR
Intervention: Standard 10-day self-isolation
Number of subjects: 16014
Study 38597249 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety operating protocol with temperature and oxygen saturation checks and SARS-CoV-2 testing
Number of subjects: 16014
Study 38597341 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical orthodontic treatment (including facemask, reverse Twin Block, orthodontic removable traction appliance, chin cup, tandem traction bow appliance, mandibular headgear)
Number of subjects: 1169
Study 38597341 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemask treatment
Number of subjects: 1169
Study 38597341 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical orthodontic treatment (surgical miniplates, facemask or Class III elastics)
Number of subjects: 1169
Study 38597341 — intervention group
Group type: COMPARATOR
Intervention: Facemask
Number of subjects: 1169
Study 38597341 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemask with RME
Number of subjects: 1169
Study 38597341 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating rapid maxillary expansion and constriction
Number of subjects: 1169
Study 38597388 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic completion total gastrectomy (LCTG)
Number of subjects: 46
Study 38597388 — intervention group
Group type: COMPARATOR
Intervention: Open completion total gastrectomy (OCTG)
Number of subjects: 46
Study 38597399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation plus systemic therapy (AS)
Number of subjects: 369
Study 38597399 — intervention group
Group type: COMPARATOR
Intervention: Ablation alone (AB)
Number of subjects: 369
Study 38597636 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary plasma samples
Number of subjects: 270
Study 38597636 — intervention group
Group type: COMPARATOR
Intervention: Venous plasma samples
Number of subjects: 270
Study 38597735 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 21
Study 38597860 — intervention group
Group type: EXPERIMENTAL
Intervention: Posoleucel, a multivirus-specific T cell therapy
Number of subjects: 0
Study 38597864 — intervention group
Group type: EXPERIMENTAL
Intervention: AT-001 (selective aldose reductase inhibitor) administered twice daily for 15 months
Number of subjects: 691
Study 38597864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 691
Study 38597988 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg oral THC
Number of subjects: 12
Study 38597988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 38598132 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic handheld devices for PROMs
Number of subjects: 1342
Study 38598227 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (100 impulses of 0.1mJ/mm/cm2 in gastrocnemius muscle, 3 times weekly for 3 weeks)
Number of subjects: 138
Study 38598227 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Number of subjects: 138
Study 38598227 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (no shockwaves delivered)
Number of subjects: 138
Study 38598229 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab (subcutaneous injections at FDA-approved dosing schedule for psoriasis over 24 weeks)
Number of subjects: 14
Study 38598229 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 14
Study 38598401 — intervention group
Group type: EXPERIMENTAL
Intervention: ROBOT group (SAR)
Number of subjects: 33
Study 38598401 — intervention group
Group type: COMPARATOR
Intervention: COMPUTER group
Number of subjects: 33
Study 38598401 — intervention group
Group type: COMPARATOR
Intervention: CONTROL group
Number of subjects: 33
Study 38598511 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational handout accompanying LCS results delivery
Number of subjects: 389
Study 38598511 — intervention group
Group type: COMPARATOR
Intervention: Standardized form letter of LCS results
Number of subjects: 389
Study 38598516 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsaclisib + rituximab (Treatment A)
Number of subjects: 50
Study 38598516 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsaclisib + rituximab + bendamustine (Treatment B)
Number of subjects: 50
Study 38598516 — intervention group
Group type: EXPERIMENTAL
Intervention: Parsaclisib + ibrutinib (Treatment C)
Number of subjects: 50
Study 38598573 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir-ritonavir
Number of subjects: 1296
Study 38598573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1296
Study 38598571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel-node biopsy only
Number of subjects: 2766
Study 38598571 — intervention group
Group type: COMPARATOR
Intervention: Completion axillary-lymph-node dissection
Number of subjects: 2766